Myasthenia Gravis Overview
Myasthenia Gravis Overview
Definition: Myasthenia gravis (MG) is a chronic disorder of the neuromuscular junction characterized by antibodies (IgG) that block acetylcholine (ACh) receptors, inhibiting nerve impulse transmission.
Primary Symptoms: The disorder is characterized by muscle fatigue and weakness that typically improves after rest.
Severe Cases: Can lead to respiratory muscle paralysis, known as a myasthenic crisis.
Neuromuscular Junction and Impairments
Normal Neuromuscular Junction:
Involves the transmission of nerve impulses from neuron to muscle via ACh, which binds to receptors on muscle fibers, leading to contraction.
Myasthenia Gravis Effect:
In MG, antibodies block ACh receptors, resulting in reduced transmission and impaired muscle contraction.
Anatomic Alterations Associated with Ventilatory Failure
Conditions contributing to ventilatory failure include:
Mucous accumulation
Airway obstruction
Alveolar consolidation
Atelectasis
Types of Myasthenia Gravis
Ocular Myasthenia Gravis:
Muscle weakness is limited to eyelids and extraocular muscles.
Generalized Myasthenia Gravis:
Muscle weakness may involve:
Bulbar muscles responsible for speech and swallowing.
Limbs and respiratory muscles.
May or may not involve ocular muscles.
Key point: Sensory function remains intact.
Etiology and Epidemiology
Common Demographics:
Most prevalent in young women aged 15-35 and older men aged 40-70.
Provoking Factors:
Emotional upset
Physical stress
Extreme temperature changes
Febrile illness
Pregnancy
Screening and Diagnosis
Clinical Presentation & History: Key to identifying MG.
Bedside Tests:
Edrophonium Test: Previously used, no longer in use.
Ice Pack Test: 5-minute application can improve ptosis (drooping eyelids).
Sleep Test: Improvement in ptosis after sleep indicates potential MG.
Immunologic Studies: Blood analysis for elevated ACh receptor antibodies.
Electrodiagnostic Studies:
Repetitive nerve stimulation
Electromyography (EMG)
Imaging: CT or MRI to detect thymoma (benign thymus tumor).
Differential Diagnosis: Necessary to rule out other diseases.
Pulmonary Function Tests: Assess ventilatory failure status.
Clinical Presentation
Facial Muscle Weakness: Includes ptosis, diplopia (double vision), and ophthalmoplegia (paralysis/weakness of eye movement).
Additional Symptoms:
Difficulty breathing, speaking, chewing, and swallowing.
Unstable gait.
Weakness in arms, hands, fingers, legs, and neck, often exacerbated by repetitive motions (reason: muscle fatigue).
Potential for descending paralysis (termed "Mind to Ground").
Edrophonium Test
Historical Background:
Used for MG diagnosis; FDA discontinued in 2018 due to safety concerns.
Mechanism: Injection of edrophonium prevents ACh breakdown, increasing ACh concentration, alleviating MG symptoms temporarily (10-minute effect).
Diagnostic Methods After Discontinuation of Edrophonium Test
Blood Tests for Antibodies: Including AChR, MuSK, and LRP4 antibodies.
Electrophysiological Tests:
Repetitive nerve stimulation and single-fiber EMG to assess communication between nerves and muscles.
Ice Pack Test: Useful specifically for ocular myasthenia gravis.
CT or MRI: Used to check for thymoma.
Antibody Testing
Current First-Line Diagnostic Tools:
AChR Antibodies: Present in approximately 85% of generalized MG cases.
MuSK Antibodies: Found in some AChR-negative patients.
LRP4 Antibodies: Detected in a smaller subset of patients.
Current Research: Investigating agrin and other novel antibodies for seronegative MG.
Electrophysiological Testing
Studies Focused on Neuromuscular Transmission:
Repetitive Nerve Stimulation (RNS): Assesses decremental responses in muscle action potentials.
Single-Fiber Electromyography (SFEMG): The most sensitive test, detecting "jitter" in muscle fiber activation.
Ice Pack Test Protocol
Procedure:
Baseline measurement of eyelid position.
Ice pack applied for 2–5 minutes.
Re-measure eyelid position after ice pack removal.
Interpretation:
Positive result: Improvement of ≥2 mm in eyelid position indicates MG.
Mechanism: Cold exposure enhances neuromuscular transmission.
Specificity: Improvement is not observed in ptosis caused by other conditions.
Clinical Manifestations in Myasthenia Gravis
Respiratory Rate: Varies based on muscle paralysis severity.
Severe Cases: Possible apnea and cyanosis.
Chest Assessment Findings:
Diminished breath sounds
Presence of crackles and rhonchi.
Pulmonary Function Test Findings
Respective Findings for Moderate to Severe MG:
Forced Expiratory Volume and Flow Rate:
Results may show decreased values with normal variations.
Lung Volume & Capacity Findings:
All measured volumes (VT, IRV, ERV, RV, VC, IC, FRC, TLC) exhibit decrease, except RV/TLC ratio which remains the same.
MIP: Maximum inspiratory pressure decreases.
Arterial Blood Gases Findings
Associated with moderate to severe MG:
Can show acute ventilatory failure with hypoxemia and acute respiratory acidosis characterized by:
Decreased pH
Increased PaCO2
Normal HCO3-
Decreased PaO2
Decreased SaO2/SpO2
Chest X-ray (CXR)
Interpretation:
Normal or demonstrate increased opacity suggesting atelectasis or consolidation.
Respiratory Monitoring Parameters
Key Measurements:
Forced Vital Capacity (VC): Should be >10 ml/kg of ideal body weight.
Maximum Inspiratory Force (NIF): More than -20 cm H2O.
Maximum Expiratory Pressure (MEP): Greater than +40 cm H2O.
Continuous monitoring of blood pressure, oxygen saturation, and arterial blood gases.
Mechanical Ventilation: Should be initiated based on clinical data indicating impending or acute ventilatory failure.
Indicators of Impending Acute Ventilatory Failure
Critical Values:
FVC < 20 mL/kg
MIP/NIF < -30 cm H2O (inspiratory strength)
MEP < 40 cm H2O (expiratory strength)
pH < 7.35
PaCO2 > 45 mm Hg
Treatment Protocols for Myasthenia Gravis
Acetylcholinesterase Inhibitors:
Mechanism: Enhance ACh action by inhibiting its breakdown.
Pyridostigmine: First-line treatment effective in mild cases.
Corticosteroids and Immunosuppressive Drugs:
Considered for chronic management; can lead to serious side effects including diabetes and osteoporosis.
Thymectomy:
Surgical removal of the thymus gland, suspected to be the source of ACh receptor antibodies.
Plasmapheresis:
A blood filtering process to reduce ACh receptor antibodies rapidly.
Intravenous Immunoglobulin (IVIG):
Another rapid treatment option.
Treatment of Pyridostigmine
Uses:
Main treatment for managing muscle weakness caused by MG and for nerve gas exposure.
Mechanism:
Pyridostigmine is an acetylcholinesterase inhibitor; it increases ACh concentration, enhancing nerve-muscle communication.
Respiratory Care Treatment Protocols
Protocol Categories:
Oxygen Therapy Protocol
Bronchopulmonary Hygiene Therapy Protocol
Lung Expansion Therapy Protocol
Mechanical Ventilation Protocol
Notes
All treatment protocols must be tailored to individual patient needs and frequently assessed due to the episodic nature of the disease and varying patient responses.